Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + irinotecan + vemurafenib
- Development stage
- Phase 3
- Lead developer
- SWOG Cancer Research Network
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A triple drug combination therapy used for the treatment of BRAF V600E-mutant metastatic colorectal cancer. This regimen combines cetuximab (an EGFR inhibitor), irinotecan (a topoisomerase I inhibitor), and vemurafenib (a BRAF V600E inhibitor) to simultaneously target multiple cancer growth pathways. Clinical trials have shown this combination significantly improves progression-free survival and response rates compared to cetuximab and irinotecan alone.
- Other names
- VICtriple therapytriple combination
02
Targets
Beyond the preview
Go deeper on cetuximab + irinotecan + vemurafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + irinotecan + vemurafenib.